Abstract
BackgroundImmune-related adverse events (irAEs) are major factors limiting optimal application of immune checkpoint inhibitors (ICIs). Up to 30% of irAEs are steroid-refractory, necessitating addition of second-line immunosuppression (2nd-line IS).1 Unfortunately,...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have